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bjectives The aim of this study was to assess risk of inpatient surgery at any time after percutane-
us coronary intervention (PCI) with drug-eluting stents (DES).
ackground Risk of adverse events, including stent thrombosis (ST), in patients undergoing surgical
rocedures with prior DES remains poorly deﬁned.
ethods Outcomes of consecutive patients having inpatient surgical procedures after PCI with DES,
laced from April 28, 2003 until December 31, 2006 at a tertiary-care medical center, were studied.
rimary and secondary end points were 30-day post-operative risk of the Academic Research Con-
ortium (ARC) deﬁnite and modiﬁed probable deﬁnitions of ST and combined 30-day post-operative
isk of death, nonfatal myocardial infarction (MI), or ST, respectively. Multivariable logistic regression
nalyses were used to determine independent risk factors.
esults Six hundred six inpatient surgeries on 481 patients with a mean time from PCI to surgery
f 1.07  0.89 years were evaluated. The primary and secondary end points occurred after 11 (2.0%)
nd 56 (9%) surgeries, respectively. Risk of the combined end point and ST decreased signiﬁcantly
n the ﬁrst 1 to 6 months after PCI (p  0.0001 and p  0.014, respectively); however, risk persisted
hen time between PCI and surgery was 12 months. Independent correlates of the combined end
oint include emergency surgery, antecedent MI, the pre-operative use of intravenous heparin, and
therosclerotic lesion length treated with DES. Oral antiplatelet status at time of surgery was not a
orrelate of events.
onclusions Risk of 30-day post-operative adverse events, including ST, remains signiﬁcantly higher
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543oronary artery stenting has increased in the last several
ears with the advent of drug-eluting stents (DES) (1). The
nitial enthusiasm for DES due to reductions in restenosis
as been tempered by concerns about stent thrombosis
ST), particularly late ST (2,3).
The risk of noncardiac surgery in weeks following percuta-
eous coronary intervention (PCI) with bare-metal stents
BMS) has been well-examined (4,5). The risk of DES
hrombosis in the perioperative period is thought related to 3
ain factors—cessation of dual antiplatelet therapy for sur-
ery, a hypercoagulable state associated with surgery, and
on-endothelialization of the stent (6). It is difficult, however,
o judge actual risk associated with surgery after DES, because
here have been no large-scale systematic reviews of the topic
nd existing reports to do not provide consistent findings
7–9). Given the currently limited data (10), we sought to
etter characterize perioperative risk associated with prior
ES use.
ethods
atient selection. This study protocol was approved by the
leveland Clinic Institutional Review Board. All patients
aving undergone PCI at the Cleveland Clinic with DES
rom 2003 until the end of 2006 were identified by the
leveland Clinic PCI database in which consecutive pa-
ients are enrolled. These patients were cross-matched with
he Cleveland Clinic operating room database to identify
hose patients having undergone any inpatient surgical
rocedure at any time point after PCI. Patients were
xcluded if they had undergone percutaneous surgical pro-
edures, experimental procedures, procedures performed
utside the main campus, or heart transplantation (Fig. 1).
urgical risk was defined by a previously validated risk
ndex (11).
Information regarding the resulting cohort of patients
as obtained from an interrogation of the medical record.
nformation was gathered regarding baseline demographic
ata, past medical history, baseline laboratory values, and
edications at time of surgery, including antiplatelet med-
cation status before and at the time of surgery (Online
ppendix 1: core variables). Creatinine clearance was cal-
ulated with the Cockroft-Gault equation.
ollow-up and clinical events. Follow-up was established by
vidence of clinical visit at or after 30 days after the surgical
rocedure or by occurrence of a primary or secondary end
oint. A clinical visit to an affiliate hospital or satellite clinic
as deemed acceptable for follow-up as electronic medical
ecords were available for review. Death was established
ither by the Social Security Death Index (last updated on
ebruary 2, 2008) and/or by review of the paper and
lectronic medical record.
Events such as myocardial infarction (MI) or ST were
djudicated (S.A.) on the basis of available clinical data. oiagnosis of perioperative MI was established with biomar-
ers, electrocardiographic evidence of ischemia or infarc-
ion, and clinical course as previously published (12). “Def-
nite” ST events were classified on the basis of the Academic
esearch Consortium (ARC) definition (13). “Probable”
T was a modified version of the ARC definition. The
odification involved excluding any unexplained death
ithin 30 days of PCI as a probable ST and requiring
vidence of an MI with evidence of ischemia in the territory
f the prior stent without another obvious cause within the
0-day post-operative period. The rationale for modifica-
ion of the definition was to avoid arbitrary assignment of
T as a cause of death in patients having undergone surgery
ithin 30 days of PCI.
nd points. The primary end point for this study was
rospectively defined as the 30-day post-operative incidence
f ST (as in the preceding), and the secondary end point was
efined as the 30-day post-operative combined incidence of
T, nonfatal MI (non-stent thrombosis), or death.
tatistical methods. Continuous data are expressed as
ean  SD or with median and 15th and 85th percentile
alues (comparable to 1 SD)
s appropriate. For continuous
ariables, Wilcoxon rank sum
ests were used to analyze 2-level
roup differences and Kruskal-
allis tests were used to analyze
-level group differences. Cate-
orical data are displayed as fre-
uencies and percentages, and
omparisons are made with chi-
quare tests (Fisher exact tests if
ppropriate).
Multivariable logistic regression analyses were used to
etermine independent risk factors for the combined end
oint. A stepwise selection approach was used with criteria
f p  0.05 for retention of variables to form an initial
odel. Bootstrap bagging methods were then used to
etermine important reliable predictors with random resam-
ling and automated analysis of 1,000 datasets for each end
oint. Covariates entered into 50% of the bootstrapping
uns were retained in the final parsimonious model.
The unit of observation for this study is surgery following
ES. To allow for at least a 15-day uninterrupted follow-up
fter index surgery, for patients with more than 1 temporally
elated surgery, the index surgery was taken as the last
urgery in the sequence for the primary analysis. General-
zed estimating equations (GEE) (14) were developed to
ccount for within-patient correlation of repeated measure-
ents (multiple surgeries/patient). Final parameter esti-
ates are the results of GEE-adjusted models.
Transformations of scale for continuous variables were
sed to meet model assumptions and for proper calibration
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosisf predictive variables with outcome. Univariable trend plots
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544ere used to display covariate relationships with outcomes.
tatistical analyses were performed with SAS version 9.1
SAS Institute, Cary, North Carolina).
esults
ive hundred forty-one patients underwent 752 inpatient
urgeries from April 28, 2003 to December 31, 2006 at the
leveland Clinic at any time after PCI with DES. Eighty-
ine surgeries from 60 patients were excluded due to
issing core variables including perioperative medication/
ntiplatelet use at or before the time of surgery, and 57
urgeries were not used in the analysis, because they oc-
urred in the 15 days before the index surgery. Results from
hese patients were analyzed separately. Therefore, 481
atients who underwent 606 surgeries comprise the princi-
al study cohort. Types of surgery are shown in Table 1.
esults of 57 surgeries not included in the analysis, due to
emporal proximity to the index procedure, are shown in
able 2. Mean time from PCI to surgery was 1.07  0.89
ears with a median of 0.88 years (15th and 85th percentiles
f 70 days and 2 years, respectively).
Patients who had surgery within 1 month of PCI were
ifferent in many ways compared with those who had
urgery at a later time point. Patients were more frequently
Figure 1. Patient Selection
All consecutive patients having undergone inpatient surgery at any time point
initially identiﬁed. The ﬁnal cohort was selected as shown in this ﬂow diagram
complete electronic and paper chart review.aking aspirin or clopidogrel within 24 h of surgery, lessften taking statins, and less likely to be hypertensive.
urthermore, duration of time (days) not taking either
spirin or clopidogrel before surgery was significantly
horter when time from PCI to surgery was 1 month
Table 3).
There were 381 surgeries (63%) performed on patients
aking neither aspirin or clopidogrel, 126 surgeries (21%)
erformed on patients taking both oral antiplatelet agents,
6 surgeries (15%) performed on patients taking only
spirin, and 6 (1%) surgeries performed on patients taking
nly clopidogrel.
percutaneous coronary intervention (PCI) with drug-eluting stents (DES) were
plete clinical follow-up includes Social Security Death Index information and
Table 1. Frequencies of Types of Surgery
Type of Surgery Frequency (%)
Cardiac 130 (22%)
Orthopedic 120 (20%)
Vascular 119 (20%)
Urologic 65 (11%)
Gastrointestinal 61 (10%)
Dermatologic 34 (5.6%)
Head/neck 32 (5.3%)
Thoracic 25 (4.1%)
Hepatobiliary 16 (2.6%)after
. *ComIntracranial 4 (0.6%)
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545T. There were 11 ST events (2.0%, 95% confidence limits:
.8% to 3.3%; 4 definite, 7 probable) during the 30-day
ost-operative period. They occurred at a median of 2 days
fter surgery. One probable ST event occurred in the cohort
f the 57 surgeries (1.8%) that was excluded from the
rimary analysis due to surgery within 15 days before the
ndex surgery. Clinical descriptions of those patients having
n ST event are shown in Table 4. There was a higher
ncidence of ST when surgery was performed within 1
onth after PCI as compared with surgery performed after
0 days after PCI (p  0.04) (Fig. 2). Over time, however,
espite a reduction in the incidence of ST, risk seems to
ersist (Fig. 3A).
Table 2. Comparison Between Patients Included in th
of Index Surgery
Variable
Included
(n 
Age 67
Creatinine clearance 83
Emergency surgery 5.
Diabetes 4
Interval (yrs) from PCI to surgery 1.07 
ASA, clopidogrel, or both at surgery 3
Stent thrombosis 1
Mean SD are shown for continuous variables.
ASA acetylsalicylic acid; PCI percutaneous coronary interventio
Table 3. Baseline Characteristics
<1 Month
(n  51)
1
(
Age, yrs* 66 (66.3 12.1) 69
Female 23 (45%) 47
Hypertension 36 (71%) 120
Diabetes 28 (55%) 69
Dyslipidemia 43 (84%) 137
Creatinine clearance* 71.3 (81.2 53) 73.8
Emergency surgery 8 (16%) 15
Surgery on aspirin 36 (71%) 58
Surgery on clopidogrel 28 (56%) 38
Beta-blockers within 24 h of surgery 41 (80%) 117
Statin use within 24 h of surgery 37 (73%) 121
Sirolimus eluting stent 35 (69%) 96
Pre-operative IV heparin 11 (22%) 30
Pre-operative EF 40 (41 7) 55
Pre-operative Hgb 10.3 (11 1.7) 12.3
Pre-operative WBC 9 (11.6 8) 7.2
Days before surgery ASA stopped 0 (1.27 2.5) 2
Days before surgery clopidogrel stopped 0 (1.8 3.2) 5
*Median (mean SD) shown for continuous variables.ASA acetylsalicylic acid; EF ejection fraction; Hgb hemoglobin; PCI percutaneous coronary inteUnivariate correlates for the 30-day risk of ST include: a
ower pre-operative ejection fraction (p  0.004), use of IV
eparin in the pre-operative period (up until the time of
urgery) (p  0.006), absence of hypertension (p  0.02),
se of aspirin within 24 h of surgery (p  0.03), and a lower
ean creatinine clearance (p  0.05). A multivariable
odel was not constructed for the end point of ST, due to
he small absolute number of events.
ombined events. The 30-day post-operative combined
nd point occurred after 56 (9%, 95% confidence interval:
% to 12%) surgeries in this cohort. There were 32 (5.0%)
eaths and 23 (4.1%) nonfatal MIs (non-ST) within the
0-day post-operative period. Surgeries that were per-
alysis Versus Those Excluded Due to Timing
nts Excluded Patients
(n  57)
p
Value
65 12 0.21
83 55 0.68
11% 0.16
54% 0.09
0.78  0.64 0.03
56% 0.0042
1 0.97
ime From PCI to Surgery
p Value
nths
47)
6–12 Months
(n  144)
>12 Months
(n  264)
11.5) 68 (66.9 10.9) 67 (67.4 10) 0.81
33 (23%) 69 (26%) 0.013
129 (90%) 231 (88%) 0.003
54 (38%) 108 (41%) 0.11
126 (88%) 253 (96%) 0.003
43) 89.7 (90 45) 76 (83 49) 0.087
3 (2.1%) 9 (3.4%) 0.0001
46 (32%) 76 (29%) 0.0001
23 (16%) 43 (16%) 0.0001
129 (90%) 225 (86%) 0.12
129 (90%) 224 (85%) 0.03
104 (72%) 194 (73%) 0.23
28 (20%) 40 (15%) 0.44
13.2) 55 (49.8 13.2) 55 (51 13.1) 0.0021
2) 13 (13 2.1) 12.5 (12.4 2) 0.0001
3.6) 6.9 (7.9 3.4) 7.5 (8.5 5.3) 0.0004
6.44) 5 (5.8 7.9) 5 (6.0 8.8) 0.0001
10.4) 5.5 (7.1 11) 5 (11.5 54) 0.0001e An
Patie
606)
11
47
8%
3%
0.89
7%
1T
–6 Mo
n  1
(67.5
(32%)
(82%)
(47%)
(93%)
(80
(10%)
(39%)
(26%)
(80%)
(83%)
(65%)
(21%)
(50
(12
(8.1
(4.6
(6.2rvention; WBCwhite blood cell count.
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546ormed within 1 month of PCI were associated with a much
igher risk (p  0.0001) (Fig. 2). As with ST, despite a
eduction in risk over time, risk persisted even when surgery
as performed as far out as 2 to 3 years after PCI (Fig. 3B).
Emergency surgery and high-risk surgeries were significant
nivariate predictors of the combined end point (p 0.001), as
as use of clopidogrel (p 0.002) or aspirin (p 0.008) in the
4 h before surgery. These variables were often interrelated.
ther univariate correlates of the combined end point included
ower pre-operative creatinine clearance (p  0.01), lower
re-operative ejection fraction (p 0.001), lower pre-operative
emoglobin (p  0.001), and elevated pre-operative white
lood cell count (p  0.0002). Furthermore, a shorter interval
days) of not taking aspirin before surgery was also noted to be
significant univariate correlate (p  0.043).
Independent correlates for the 30-day post-operative
ombined end point include MI in the 30 days before
urgery (p  0.0004), use of pre-operative IV heparin (p 
.0004), emergency surgery (p  0.004), and length of the
therosclerotic lesion where DES was placed (p  0.02)
Table 4. Description of Stent Thrombosis Events
Patient #
Aspirin at
Surgery
Clopidogrel
at Surgery Stent Type/Vessel
Sten
(m
1 Yes Yes Paclitaxel/LAD 3.5
2 Yes Yes Sirolimus/LAD 2.5
3 Yes No Sirolimus/LCx 3.5
4 Yes Yes Sirolimus/diagonal/LAD 2.5
5 No No Sirolimus/RCA 3.0
6 No No Sirolimus/ R PDA 2.5
7 Yes Yes Paclitaxel/LCx 3.0
8 Yes No Sirolimus/LAD/diagonal 2.5
9 No No Sirolimus/LAD 3.5
10 Yes No Sirolimus/R PDA 2.5
11 No No Sirolimus/obtuse marginal 2.5
GI gastrointestinal; LAD left anterior descending coronary artery; LCx left circumflex artery; R
Figure 2. Events as Stratified by Time From PCI to Surgery
Stent thrombosis and the combined end point were signiﬁcantly higher when
Despite a reduction in events over time, events seem to persist over time.Table 5). Once these variables were considered, use of
spirin or clopidogrel in the 24 h before surgery was not a
ignificant predictor of the combined end point (p  0.4).
A separate analysis of the 30-day post-operative com-
ined end point was performed, having excluded coronary
rtery bypass grafting surgeries (n 483). The incidences of
T and the combined primary end point were 2.1% and
.3%, respectively, and were not significantly different from
he overall population (p  0.4). Independent correlates for
he 30-day post-operative combined end point included MI
n the 30 days before surgery (p  0.0001), use of pre-
perative IV heparin (p  0.0004), and higher surgical risk
p  0.003) (Table 6). Again, use of aspirin or clopidogrel
n the 24 h before surgery was not a significant correlate of
he combined end point (p  0.8).
iscussion
his study reports upon the heretofore incompletely de-
cribed 30-day post-operative risk associated with prior
Time From PCI to
Surgery (days) Surgery
Definite vs. Probable
Stent Thrombosis
5 Cardiac (noncoronary) Probable
11 Thoracic Probable
18 Cardiac (coronary  valve Probable
33 Vascular Probable
50 Orthopedic Probable
150 Vascular Probable
182 Vascular Deﬁnite
235 Vascular Probable
351 GI Deﬁnite
552 Thoracic Deﬁnite
1,103 GI Deﬁnite
ight coronary artery; R PDA right posterior descending artery.
from percutaneous coronary intervention (PCI) to surgery was 1 month.t Size
m)
 20
 23
 23
 13
 18
 8
 24
 23
 13
 8
 13time
D
4
o
s
c
F
t
t
s
b
p
c
w
w
c
t
p
L
i
b
m
d
o
e
d
d
e
s
c
w
n
v
j
a
b
l
a
p
p
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 6 , 2 0 0 9 Anwaruddin et al.
J U N E 2 0 0 9 : 5 4 2 – 9 Drug-Eluting Stents and Surgical Risk
547ES use. Overall risk of ST in this cohort was 2.0%, with
definite and 7 probable adjudicated events. A similar risk
f ST was noted when coronary artery bypass grafting
urgeries were excluded from the analysis. Overall risk of the
ombined end point of death, nonfatal MI, or ST was 9.0%.
or ST, risk seemed to be significantly higher when the
ime interval between PCI and surgery was shorter. Fur-
hermore, although the risk of both the primary and
econdary end points decreased for the increasing interval
etween PCI and surgery, the risk of an event seems to
ersist—with an approximately 1% risk of thrombosis oc-
urring when the time interval between PCI and surgery
as between 2 to 3 years.
Emergency surgery and MI in the 30 days before surgery
ere independent correlates of the 30-day post-operative
ombined end point. They serve to validate the model for
Figure 3. Stent Thrombosis and Combined End Point Events as Function
of Time From PCI
Surgeries were divided into quintiles on the basis of time. The mean num-
ber of events in each quintile is plotted at the average time. Error bands
represent 68% conﬁdence intervals, similar to 1 SD. (A) Stent thrombosis
events as a function of time from percutaneous coronary intervention (PCI).
(B) Combined end point events as a function of time from PCI.he combined end point, because they have been shown toredict complications in noncardiac surgery (11,15,16).
onger atherosclerotic target lesion length was also an
ndependent correlate of the 30-day post-operative com-
ined end point. Longer atherosclerotic coronary lesions
ight be a surrogate for more extensive coronary artery
isease burden as well as use of longer stents and/or
verlapping/bifurcating stents, all of which might impact
ndothelialization of the DES. In this cohort, however,
irect PCI-related characteristics such as stent length or
iameter were not independent predictors of the combined
nd point.
The use of IV heparin in the pre-operative period also
eems to be a robust independent predictor of the 30-day
ombined end point. A possible explanation for this is the
ell-described heparin rebound phenomenon (17). Intrave-
ous unfractionated heparin also might cause platelet acti-
ation (18,19). The combination of these effects, in con-
unction with the hypercoagulable state known to occur
fter surgery, could serve to explain the apparent correlation
etween heparin use and risk (20).
Premature cessation of oral antiplatelet therapy, particu-
arly within 1 year after PCI with DES, has been identified
s a factor associated with increased risk of ST (21). In the
erioperative setting, however, continuation of oral anti-
latelet therapy might not be considered feasible, due to
ncreased risk of significant bleeding (22). In this analysis,
Table 5. Multivariable Predictors for the 30-Day Combined End Point
Risk Factors
Odds
Ratio 95% CI
p
Value
MI within 30 days of surgery 6.05 2.19–16.7 0.0004
Pre-operative IV heparin use 3.22 1.68–6.16 0.0004
Emergency surgery 4.26 1.56–11.6 0.004
Longer lesion length (mm)* 1.09 1.01–1.17 0.02
Lower pre-operative EF† 1.54 0.97–2.45 0.07
Shorter time from PCI to surgery‡ 0.87 0.69–1.1 0.2
Aspirin and/or clopidogrel use 24 h before surgery 1.32 0.7–2.46 0.4
*Squared transformation. †Inverse transformation. ‡Natural log transformation.
CI confidence interval; EF ejection fraction; IV intravenous; MImyocardial infarction;
PCI percutaneous coronary intervention.
Table 6. Multivariable Predictors for the 30-Day Combined End Point
(Excluding CABG)
Risk Factors
Odds
Ratio 95% CI
p
Value
MI within 30 days of surgery 14.42 3.84–54.2 0.0001
Pre-operative IV heparin use 4.08 1.87–8.88 0.0004
Higher surgical risk 3.51 1.53–8.03 0.003
Shorter time from PCI to surgery* 0.94 0.69–1.26 0.7
Aspirin and/or clopidogrel use 24 h
before surgery
1.09 0.52–2.3 0.8
*Natural log transformation.CABG coronary artery bypass grafting; other abbreviations as in Table 5.
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548urgery within 1 month of PCI was more likely to have been
erformed on patients taking aspirin or clopidogrel. Aspirin
se in the perioperative period was also identified as a
nivariate predictor of both end points. Although this is
ikely due to timing of surgery after PCI, it might also
eflect a potentially sicker patient population needing more
rgent or emergent surgery shortly after PCI.
Attempting to dissect out the interplay and importance of
hese variables, the multivariable model for the 30-day
ost-operative combined end point demonstrates that tak-
ng aspirin and/or clopidogrel in the 24 h before surgery was
ot protective (p  0.3), irrespective of interval between
CI and surgery. Although the reason for this remains
ncertain, it suggests oral antiplatelet therapy in the peri-
perative period might not protect against adverse events,
ncluding ST. In this cohort, there were 3 ST events
Patients #7, #8, and #10 in Table 4) observed in surgeries
erformed on patients taking dual antiplatelet therapy (2
aking aspirin, 1 taking aspirin and clopidogrel) at an
verage of 323 days after PCI.
That IV heparin was a correlate of adverse outcomes and
ral antiplatelet therapy was not apparently protective of
uch events suggests that these agents might be surrogates
or clinical instability, surgical risk, or perceived risk of ST.
or example, heparin was more often used before higher-
isk surgeries (vascular, cardiovascular), and oral antiplatelet
herapy was more likely to be continued when time from
CI to surgery was 1 month. Furthermore, emergent
urgery often precluded any planned discontinuation of oral
ntiplatelet therapy. However, within the multivariable
odel, effects of IV heparin seemed to be independent of
urgical risk and timing of surgery—even when higher-risk
urgeries were removed from the analysis (data not shown).
t might be that unmeasured variables, such as non-
ndothelialization of the stent, might be vitally important in
etermining risk—particularly in those undergoing surgery
oon after PCI and while taking oral antiplatelet therapy.
The implications of these findings are important and
idely applicable, particularly because surgery after PCI can
e unpredictable. The incidence of a surgical procedure
ithin 1 year after PCI with DES is approximately 4.4% (P.
erger, personal communications, May 2008).
Given widespread use of DES in PCI, the role of proper
re-operative risk stratification remains crucial in those with
revious DES placement. The primary objective should be
o delay elective surgery as far from the time of PCI as
ossible for risk reduction. In this cohort, the rate of ST was
% when surgery was within 1 month of PCI, 2.9% when
erformed between 1 and 6 months after PCI, 1.4%
etween 6 and 12 months, and 0.78% when surgery was
12 months from PCI. One caveat is that delaying surgery
oes not eliminate the risk of adverse post-operative
vents, including ST. Furthermore, performing surgery
ith patients taking dual antiplatelet therapy might not Ponfer protection from adverse post-operative events,
ncluding ST.
tudy limitations. This study remains limited in that it is
erived from a single-center, retrospective cohort. The
etrospective nature of the study combined with the need to
ombine DES and surgical databases to derive the patient
ohort might have resulted in an underestimation of true
ncidence of perioperative ST, because events occurring
uring the period of antiplatelet therapy withdrawal before
urgery would have been missed. Furthermore, although the
ncidence of ST in this cohort was high, the absolute
umber of events remains low. This precluded any robust
tatistical analysis to further define the relationships among
ariables.
For purposes of the principal statistical analysis and to
llow at least a 15-day follow-up without another surgery,
e excluded all surgeries performed within 15 days of a
ubsequent “index” surgery. After the 57 surgeries that were
xcluded due to this logic employed to allow for a 30-day
ollow-up after any surgery, one probable ST (1.7%) oc-
urred before the index surgery and was therefore censored
rom the principal analysis. This incidence is similar to that
bserved for ST events in those surgeries that were included
n the analysis (p  0.97). Furthermore, there were only a
ew differences in baseline characteristics between included
urgeries and excluded surgeries (Table 2). Given the reason
or exclusion of these patient surgeries, these differences are
xpected. As such, we do not believe that selective exclusion
f these surgeries would have significantly altered the
nterpretation of patient outcomes.
We also acknowledge the limitations of our definition of ST
nd its application in the perioperative period. A modified
ersion of the ARC definitions was used to exclude perioper-
tive events unrelated to ST. Because the perioperative setting
an complicate the adjudication of an accurate diagnosis, the
econdary combined end point was also evaluated, but it is
ossible that the relationship between death or MI and ST was
isclassified in some patients
Finally, we acknowledge the possibility that not all
ollow-up events were captured. Routine follow-up was not
rotocolized. However, given the large catchment area of
he hospital and affiliate hospitals linked by electronic
edical records, 87.2% of patients had documented
ollow-up within 30 days, and 85% had a post-procedural
lectrocardiogram. All patients had known vital status at 30
ays. Furthermore, those patients who received both cardiac
nd noncardiac care at this institution were more likely to
eturn for follow-up or complications related to either issue.
onclusions
e present the experience from a retrospective cohort
aving undergone inpatient surgical procedures after prior
CI with DES. The 30-day post-operative risk of ST was
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549.0%, and that of ST, nonfatal MI, or death was 9.0%. Risk
eems to be highest when the interval from PCI to surgery
s 1 to 2 months, but some appreciable risk endures over
t least 2 to 3 years. Use of perioperative oral antiplatelet
gents might not protect against and use of pre-operative IV
eparin might increase the risk of events in the post-
perative period. Risk seems to be higher with antecedent
I, longer atherosclerotic lesion length, or emergency
urgery. These findings need to be validated in a large
rospective data set but, pending this, assist the clinician in
aking decisions about surgeries in patients with DES.
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